ALSO NOTED: Bavarian Nordic earns milestone payment; Cyclacel acquires Align Pharmaceuticals; and much more...

> Bavarian Nordic has earned a $50 million advanced payment for achieving milestones outlined in its contract to provide smallpox vaccine to the U.S. government. Report

> Coley Pharmaceuticals of Wellesley, MA has adopted a shareholder rights program. Release

> Cyclacel Pharmaceuticals has acquired Align Pharmaceuticals for about $3.5 million in cash. Release

> UK-based Shire Pharmaceuticals is selling a block of medicines to Almirall of Spain for $213 million. Report

> A Florida jury ruled for Merck in yet another Vioxx case, bringing the drug maker's record to 11-5 in trials related to the drug. Report

> Eli Lilly is owning up to Zyprexa's ills in new warnings added to the medicine's label. Report

And Finally...Too much debt? Blame it on your genes. New research indicates that our genes may play a key role in our economic behavior. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.